secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2022-07-05T23:59:59+00:00
Accession:  0000950170-22-012442
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Dyne's IND for DYNE-251 in Duchenne muscular dystrophy
--------------------------------------------------------------------------------

- FDA cleared IND and lifted clinical hold for DYNE-251, targeting exon 51 skipping in DMD.
- Dyne expects to begin dosing patients in a Phase 1/2 trial in mid-2022.
- Trial will enroll 30–50 males ages 4–16, both ambulant and non-ambulant.
- Endpoints include safety, dystrophin expression by Western blot, PK/PD, and muscle function.
- Company will release trial design details and data timing upon first dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022012442/0000950170-22-012442-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017022012442/dyn-20220705.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-012442

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer